Regulation of Serum Thrombopoietin Levels by Platelets and Megakaryocytes in Patients with Aplastic Anaemia and Idiopathic Thrombocytopenic Purpura

Summary

To clarify the regulatory mechanism of thrombopoietin (TPO, c-Mpl ligand) in chronic thrombocytopenic conditions, we determined TPO levels in the sera of patients with aplastic anaemia (AA; n = 26) and idiopathic thrombocytopenic purpura (ITP; n = 32) by an enzyme-linked immunosorbent assay. Despite a similarity in platelet counts, serum TPO levels in the AA group were markedly higher than those in the ITP group: 20.41 ± 9.71 f mol/ml (mean ± SD) and 1.66 ± 0.55 f mol/ml, respectively, both of which were significantly elevated compared to normal subjects (n = 41; 1.22 ± 0.37). In both groups, serum TPO level showed an inverse correlation with the platelet count. We determined the megakaryocyte volume using bone marrow clot section and found that it was markedly small in the AA group; while in the ITP group it was augmented with a correlation to serum TPO level. Our findings suggest that TPO levels may be regulated not only by platelets but also megakaryocytes in AA and ITP.

• References

• 1 Shadduck RK. Aplastic anemia. In: Williams Hematology, 5th ed Beutler E, Lichtman MA, Coller BS, Kipps TJ. eds. McGraw-Hill Inc; New York, NY: 1995: 238-251
• 2 Camitta BM, Storb R, Thomas ED. Aplastic anemia: pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med 1982; 306: 645-652
• 3 Mangan KF, Mullaney MT, Rosenfeld CS, Shadduck RK. In vitro evidence for disappearance of erythroid progenitor T suppressor cells following allogeneic bone marrow transplantation for severe aplastic anemia. Blood 1988; 71: 144-150
• 4 Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980; 56: 329-343
• 5 McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981; 304: 1135-1147
• 6 Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40
• 7 Kaushansky K. Thrombopoietin: The primary regulator of platelet production. Blood 1995; 86: 419-431
• 8 Sohma Y, Akahori H, Seki N, Hori T, Ogami K, Kato T, Shimada Y, Kawamura K, Miyazaki H. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS lett 1994; 353: 57-61
• 9 Kato T, Ogami K, Shimada Y, Iwamatsu A, Sohma Y, Akahori H, Horie K, Kokubo A, Kudo Y, Maeda E, Kobayashi K, Ohashi H, Ozawa T, Inoue H, Kawamura K, Miyazaki H. Purification and characterization of thrombopoietin. J Biochem 1995; 118: 229-236
• 10 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-2730
• 11 Nichol JL, Hokom MM, Homkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, Bartley TD, Choi E, Bogenberger JB, Skrine JD, Knudten A, Chen J, Trail G, Sleeman L, Cole S, Grampp G, Hunt P. Megakaryocyte growth and development factor: analyses of in vitro effects on human megakaryopoie-sis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95: 2973-2978
• 12 Ulich TR, de Castillo J, Yin S, Swift S, Padilla D, Senaldi G, Bennett L, Shutter J, Bogenberger K, Sun D, Samal B, Shimamoto G, Lee R, Stein-brink R, Boone T, Sheridan WT, Hunt P. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971-976
• 13 Tahara T, Usuki K, Sato H, Ohashi H, Morita H, Tsumura H, Matsumoto A, Miyazaki H, Urabe A, Kato T. A Sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and patients with hematopoitic disorders. Br J Haematol (in press).
• 14 Branehög I, Kutti J, Ridell B, Swolin B, Weinfeld A. The relation of throm-bokinetics to bone marrow megakaryocytes in idiopathic thrombocytopenic purpura (ITP). Blood 1975; 45: 551-562
• 15 Boeryd B, Ganelius T, Lundin P, Mellgren J. Counting and sizing of tumor metastases in experimental oncology. Int J Cancer 1966; 1: 497-502
• 16 McCarty JM, Sprugel KH, Fox NE, Sabath DE, Kaushansky K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995; 86: 3668-3675
• 17 Hoffman R, Mazur E, Bruno E, Floyd V. Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies. N Engl J Med 1981; 305: 533-538
• 18 Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Salis CJM, Orkin SH. Transcription factor NF-E2 is required for platelet formation independent of the action of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695-704
• 19 Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-2161
• 20 Devili N, Wendling F, Cosman D, Titeux M, Florindo C, Dusanter-Fourt I, Schooley K, Methia N, Charon M, Nador R, Bettaieb A, Vainchenker W. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85: 391-401
• 21 Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood 1995; 86: 2494-2499
• 22 Kaushansky K, Broudy VC, Grossman A, Humes J, Lin N, Ren HP, Bailey MC, Papayannopoulou T, Forstrom JW, Sprugel KH. Thrombopoietin expands erythroid progenitors, increased red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96: 1683-1687
• 23 Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, Rowan C, Dwyer E, Nichol JL, Grasel T, Wilson J, Steinbrink R, Hecht R, Winters D, Boone T, Hunt P. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486-4492